Assembly Biosciences, Inc. reported progress in its clinical development of antiviral candidates, with data from multiple programs expected in 2025. Specifically, interim Phase 1b data for long-acting ...

– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...

Microfactories are not just smaller replicas of mega-factories. They operate with radically different assumptions. Data is ...